Aprea Therapeutics, Inc. (APRE) vs IMMURON (IMRN)

Aprea Therapeutics, Inc. and IMMURON are both Biotechnology companies. Aprea Therapeutics, Inc. and IMMURON are of similar size ($9.8M and $9.6M). IMMURON grew revenue faster over the last twelve months: −6.62% against −81.0%. Aprea Therapeutics, Inc. has the higher net margin (0.00% vs −262.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, IMMURON leads on 7 and Aprea Therapeutics, Inc. on 5.

Valuation

Metric APRE IMRN Biotechnology median
P/E n/m n/m 7.88
P/S 144.15 n/m 11.47
P/B 1.07 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.00 0.93 0.74
EV/Sales (0.18) (3.50) 10.73
Earnings yield (140.26%) (1.75%) (28.84%)
Free cash flow yield (29.60%) 0.00% (23.03%)

Profitability

Metric APRE IMRN Biotechnology median
Gross margin 100.00% 71.28% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (262.71%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (47.44%) 0.00% (57.72%)
Return on assets (41.30%) 0.00% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric APRE IMRN Biotechnology median
Revenue growth (TTM) (80.99%) (6.62%) 5.64%
EPS growth (last fiscal year) 17.87% 37.29% —
Revenue growth, 5-year CAGR — 116.96% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric APRE IMRN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 13.55 7.17 4.73
Net debt to EBITDA 1.11 2.25 0.96

Dividend

Metric APRE IMRN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric APRE IMRN Biotechnology median
Market cap 9.82m 9.60m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack